NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization303.29 mln
Float38.85 mln
Earnings Date08/11/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-0.62
Highly suspicious
1-Year Forecast
9.08
Transformational upside
Relative Strength
79
/ 100
Strongly outperforming
Debt / Equity
0.10
Very low leverage
ROE
-93.01
Deeply negative
Business Description
AC Immune SA is a Switzerland-based clinical-stage company focused on fighting neurodegenerative diseases by targeting the misfolded proteins that drive conditions such as Alzheimer's and Parkinson's. Its two core platforms produce both biological therapies and small-molecule drugs designed to seek out and act on these harmful proteins, supporting a broad pipeline of treatments and diagnostic tools. The company works alongside major partners including Genentech, Eli Lilly, and Janssen Pharmaceuticals to advance its programs through development.
